To inquire about our available technologies, call our office (813) 745-6828

Name & Description Number
Protein Diagnostic: Quantum Dots Conjugated with Antibodies for Early Cancer Detection 04A064
Protein Signature: Discriminating Common Adenocarcinomas 05A014
Genetic Signature: Metastatic Melanoma Stage Identification 06B073
Plasma Protein Biomarker: Diagnosis of Ovarian Cancer 06B098
Protein Biomarker: Predicting Response to Immunosuppression in MDS 07A056
Genetic Signature: Predicting Tumor Aggressiveness 07B108
Protein Biomarker: Diagnostic biomarker for Acute Myeloid Leukemia (AML) M5 Subtype 07B113
Genetic Signature: Seven-Gene Signature Test for Prediction of Breast Cancer Recurrence 08A016
Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence 08MA005
Genetic Signature: Immune-related Gene Signature to Influence Treatment Decisions and Predict Immunotherapy Outcomes in Cancer 09MA014
Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP) 10MA009
Genetic Signature: Novel Gene Signature for Prediction of Response to Standard of Care for High Grade Gliomas 10MA013
Molecular Imaging Probe: Breast Cancer-Targeted Probe Set for Improved Detection of Lymph Node Metastases 10MA024
Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery 10MB069N
Genetic Signature: New CREB Gene Signature for Improved Ovarian Cancer Therapy Management 11MA006
Protein Diagnostic: New Receptor Tyrosine Kinase Assay for Patient Treatment Selection Based on Protein-Protein Bindi 11MA014
Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images 11MA022
Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma 11MA026N
Genetic Signature: Method of Detecting MDS Using hTERT Activity 11MB061N
Molecular Imaging Probe: Synthetic Fluorescent Probe for Improved Detection and Tumor Removal in Pancreatic Cancer Patients 11MB064
Gene Signature for Immunotherapy Response Prediction in Cancer Based on Nuclear Factor-kappa B 11MB069
Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia 11MB072N
Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins 11MB087N
Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC 12MA023N
Genetic Signature: Novel Gene Polymorphisms to Predict Prostate Cancer Recurrence and Guide Therapy Options 12MA045
Genetic Signature: Gene Expression Signature to Determine the Benefit of Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer 12MA069
Molecular Imaging Probe: A Novel 18F Scaffold for Preparing Targeted PET Imaging Probess 12MB104
Protein Diagnostic: Phosphorylated STAT3 Protein as a Novel Biomarker of Graft Versus Host Disease 13MA002
Multiplex Diagnostic: Detection of Minimal Residual Disease in Multiple Myeloma Using RNA Sequencing and Mass Spectrometry 13MA009
Genetic Signature: Gene Signature Predicts Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer 13MA036
Imaging: Decision Support Tool for Oncology Treatment that Analyzes Radiological Images 13MB047
Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma 13MB048N
Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis 13MB054
Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma Multiforme 13MB055
Molecular Imaging: PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging 13MB056N
miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs) 13MB078
miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma 13MB080
Protein Biomarker: Expression of WEE1 and PAXIP1 Can Select Patients who Respond to WEE1 Inhibitor Therapys 14MA001
Gene Signature to Predict Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery 14MA008
Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy 14MA052N
Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detecti 15MA015
Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation as MDS Biomarkers 15MA021N
Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration 15MA031N
Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes 15MB042N
Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression 15MB065
Genetic Signature: Gene Signature to Distinguish Lung Squamous Cell Carcinoma from Metastatic Head & Neck Squamous Cell Carcinoma 16MB040
Protein Biomarker: Method for Measuring MRE11 in Muscle –Invasive Bladder Cancer to Predict Chemoradiation Response Using AQUA 16MB041
Protein Biomarker: Diagnostic to Determine which Low-Risk MDS Patients to Treat with Lenalidomide to Restore Sensitivity to Erythropoietin 16MB042
Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent 16MB044
miRNA Diagnostic: MicroRNA Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma 16MB066
miRNA Diagnostic: miRNA Signature for Non-invasive Early Detection of Malignancy in IPMN 17MA001
Molecular Imaging: Predicting Response to Adjuvant Ipilimumab Treatment in Melanoma Using a Novel Algorithm to Analyze Nitric Oxide Levels in Peripheral Blood Immune Cells 17MA002N
Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment 17MA025
Genetic Signature: Gene Signature to Distinguish between Metastatic Urothelial Carcinoma and Squamous Cell Carcinoma (Primary Lung and Metastatic Head & Neck) 17MB044
Mathematical Modeling: Methods for the Treatment of Prostate Cancer Using Intermittent Adaptive Therapy 18MB055N
Mathematical Modeling: Predict Patient-Specific Radiotherapy Responses Using a Proliferation Saturation Index in an Adaptive Bayesian Approach 18MB083N
Mathematical Modeling: Novel algorithm that measures obesity related risks of surgery using segmentation of adiposity on abdominal CT scans 19MA001N